Filling the antimicrobial drug discovery pipeline is now more challenging than ever. The ever-mounting problem of resistance fuels the need for new agents. The stunning progress in 'omics'-scale research is now available to the antimicrobial community. Available screening methods and targets present the first pass at exploitation of new opportunities.